Evidence map›Paper›PMID 41867952›Full record

ReviewFrontiers in chemistry2026

Emerging insights into chemistry and therapeutic potentials of functionalized hexahydroquinolines.

Gbolahan O Oduselu, Rhoda O Olatuyi, Omowunmi O Fatoki, Damilola S Bodun, Promise E Sunday, Wellington Oyibo, Olayinka O Ajani

Erratum issuedAbstract readReview
In one paragraph

Review in Frontiers in chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Gbolahan O OduseluWest African Center for Cell Biology of Infectious Pathogens (WACCBIP), College of Basic and Applied Sciences, University of Ghana, Accra, Ghana.
Rhoda O OlatuyiDepartment of Chemistry, College of Science and Technology, Covenant University, Ota, Nigeria.
Omowunmi O FatokiDepartment of Chemistry, College of Science and Technology, Covenant University, Ota, Nigeria.
Damilola S BodunDepartment of Chemistry, College of Science and Technology, Covenant University, Ota, Nigeria.
Promise E SundayDepartment of Pharmaceutical and Medicinal Chemistry, University of Uyo, Uyo, Nigeria.
Wellington OyiboANDI Center of Excellence for Malaria Diagnosis, College of Medicine, University of Lagos, Lagos, Nigeria.
Olayinka O AjaniDepartment of Chemistry, College of Science and Technology, Covenant University, Ota, Nigeria.

Funding

Wellcome Trust
6 · The paper itself

Abstract

Quinolines are well-established scaffolds in drug discovery and form the core of many FDA-approved medicines. Among their reduced analogues, hexahydroquinolines (HHQs) have gained increasing attention due to their structural adaptability and broad pharmacological relevance. Research has largely focused on the 1,4,5,6,7,8-hexahydroquinoline framework, although interest in other variants, including 2-oxo derivatives, is steadily growing. This review summarizes recent progress in HHQ chemistry, with emphasis on synthetic strategies and emerging therapeutic applications. Traditional multicomponent reactions such as the Hantzsch, Antaki, and Stankevich methods are discussed alongside more recent green synthetic strategies, including the use of natural and heterogeneous catalysts, catalyst-free protocols, and alternative activation techniques such as ultrasonication. These sustainable protocols often provide improved yields under milder conditions and shorter reaction times. A recurring feature of HHQ synthesis is the preferential formation of 5-oxo derivatives. The mechanistic basis for this structural dominance and the synthetic approaches for the other underexplored HHQ chemotypes are examined. From a biological perspective, HHQs have demonstrated notable activity across several therapeutic areas, including antiprotozoal potential against

Indexed as

antiprotozoal agentsdrug discoveryheterocyclic compoundspharmacological potentialquinoline

Identifiers

PMID41867952
PMCPMC12999796

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.